Interstitial lung involvement in rheumatoid arthritis patients treated with abatacept: a prospective observational study
Authors' conclusion
In conclusion, the presence of ILD did not affect the retention rate of the drug, suggesting a role for abatacept in the treatment of RA-ILD.
Study context
- Population
- Consecutive rheumatoid arthritis (RA) patients on ongoing abatacept treatmentILD in 20.6% at enrolment
- Participants
- 325 patients
- Exposure
- RA with ILD vs RA without ILD, all on abatacept
- Outcome
- Clinical course and incidence of ILD
- Follow-up
- 24 months
Methodological detailsmulticentre, observational
- Multicentre
- Observational
Main finding
As reported in the abstract
Incidence and clinical course of ILD
Incidence rate of new-onset ILD
0.39/100 patients/year
ILD improved or remained stable
more than 85%
Worsening of radiologic picture, mainly usual interstitial pneumonia
14.9%
Observational data: associations, not effects.
Further findings
Two-year retention rate of abatacept · 24 months
- No difference between patients with and without ILD
Safety
Abatacept discontinuation for worsening of lung function
- No patients discontinued
Original publication
Interstitial lung involvement in rheumatoid arthritis patients treated with abatacept: a prospective observational study. Clin Exp Rheumatol. Published 20 August 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →